Target Essentiality and Centrality Characterize Drug Side Effects

To investigate factors contributing to drug side effects, we systematically examine relationships between 4,199 side effects associated with 996 drugs and their 647 human protein targets. We find that it is the number of essential targets, not the number of total targets, that determines the side effects of corresponding drugs. Furthermore, within the context of a three-dimensional interaction network with atomic-resolution interaction interfaces, we find that drugs causing more side effects are also characterized by high degree and betweenness of their targets and highly shared interaction interfaces on these targets. Our findings suggest that both essentiality and centrality of a drug target are key factors contributing to side effects and should be taken into consideration in rational drug design.

[1]  Ian M. Donaldson,et al.  Literature curation of protein interactions: measuring agreement across major public databases , 2010, Database J. Biol. Databases Curation.

[2]  R. Krauss,et al.  When good drugs go bad , 2007, Nature.

[3]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[4]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[5]  Dragos Horvath,et al.  Predicting ADME properties and side effects: the BioPrint approach. , 2003, Current opinion in drug discovery & development.

[6]  Stephen J. Elledge,et al.  Profiling Essential Genes in Human Mammary Cells by Multiplex RNAi Screening , 2008, Science.

[7]  Haiyuan Yu,et al.  Network-based methods for human disease gene prediction. , 2011, Briefings in functional genomics.

[8]  Frederick W. Fraunfelder,et al.  Visual side effects associated with erectile dysfunction agents. , 2005, American journal of ophthalmology.

[9]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[10]  Livia Perfetto,et al.  MINT, the molecular interaction database: 2012 update , 2011, Nucleic Acids Res..

[11]  H. Lehrach,et al.  A Human Protein-Protein Interaction Network: A Resource for Annotating the Proteome , 2005, Cell.

[12]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[13]  A. Barabasi,et al.  Interactome Networks and Human Disease , 2011, Cell.

[14]  Mark Gerstein,et al.  The Importance of Bottlenecks in Protein Networks: Correlation with Gene Essentiality and Expression Dynamics , 2007, PLoS Comput. Biol..

[15]  Michael J. Keiser,et al.  Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.

[16]  Rafael C. Jimenez,et al.  The IntAct molecular interaction database in 2012 , 2011, Nucleic Acids Res..

[17]  P. Stenson,et al.  The Human Gene Mutation Database: 2008 update , 2009, Genome Medicine.

[18]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[19]  Ian M. Donaldson,et al.  iRefWeb: interactive analysis of consolidated protein interaction data and their supporting evidence , 2010, Database J. Biol. Databases Curation.

[20]  Sarah L. Kinnings,et al.  Novel computational approaches to polypharmacology as a means to define responses to individual drugs. , 2012, Annual review of pharmacology and toxicology.

[21]  M. Vidal,et al.  Literature-curated protein interaction datasets , 2009, Nature Methods.

[22]  Hiroaki Kitano,et al.  Structure of Protein Interaction Networks and Their Implications on Drug Design , 2009, PLoS Comput. Biol..

[23]  Martin H. Schaefer,et al.  HIPPIE: Integrating Protein Interaction Networks with Experiment Based Quality Scores , 2012, PloS one.

[24]  Yan Wang,et al.  VisANT 3.5: multi-scale network visualization, analysis and inference based on the gene ontology , 2009, Nucleic Acids Res..

[25]  S. L. Wong,et al.  Towards a proteome-scale map of the human protein–protein interaction network , 2005, Nature.

[26]  K. Shokat,et al.  Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.

[27]  Alan F. Scott,et al.  McKusick's Online Mendelian Inheritance in Man (OMIM®) , 2008, Nucleic Acids Res..

[28]  M. DePamphilis,et al.  HUMAN DISEASE , 1957, The Ulster Medical Journal.

[29]  A. Barabasi,et al.  Network medicine : a network-based approach to human disease , 2010 .

[30]  Philip M. Kim,et al.  Relating Three-Dimensional Structures to Protein Networks Provides Evolutionary Insights , 2006, Science.

[31]  Yanli Wang,et al.  PubChem: a public information system for analyzing bioactivities of small molecules , 2009, Nucleic Acids Res..

[32]  Kara Dolinski,et al.  The BioGRID Interaction Database: 2008 update , 2008, Nucleic Acids Res..

[33]  Daniel T. Larose,et al.  Discovering Knowledge in Data: An Introduction to Data Mining , 2005 .

[34]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[35]  Yoshihiro Yamanishi,et al.  Predicting drug side-effect profiles: a chemical fragment-based approach , 2011, BMC Bioinformatics.

[36]  M. Rask-Andersen,et al.  Trends in the exploitation of novel drug targets , 2011, Nature Reviews Drug Discovery.

[37]  Sandhya Rani,et al.  Human Protein Reference Database—2009 update , 2008, Nucleic Acids Res..

[38]  P. Bork,et al.  Network Neighbors of Drug Targets Contribute to Drug Side-Effect Similarity , 2011, PloS one.

[39]  A. Barabasi,et al.  An empirical framework for binary interactome mapping , 2008, Nature Methods.

[40]  A. Barabasi,et al.  The human disease network , 2007, Proceedings of the National Academy of Sciences.

[41]  David E Hill,et al.  next-generation sequencing to generate interactome datasets , 2011 .

[42]  Clare Ellis.  FDA alerts asthmatics to drug safety risk , 2003, Nature Reviews Drug Discovery.

[43]  Haiyuan Yu,et al.  Three-dimensional reconstruction of protein networks provides insight into human genetic disease , 2012, Nature Biotechnology.

[44]  Malorye Allison,et al.  Reinventing clinical trials , 2012, Nature Biotechnology.